Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib

Phase 4

Completed

• Conditions: Hepatitis B

• Registration Number: NCT00356564
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine

Detailed Description

Not available

Study Timeline

• Study Start: 2006-07
• Study First Submitted: 2006-07-25
• Study First Submitted QC: 2006-07-25
• Study First Posted: 2006-07-26
• Study Completion: 2006-12
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-11
• Last Update Posted: 2016-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• A male or female aged 7 to 9 years at the time of study entry .
• Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine or a total of 4 doses of HBV vaccine in previous vaccination studies.
• Evidence of previous hepatitis B booster vaccination or disease since administration of the fourth dose of DTPa-HBV-IPV/Hib or HBV vaccine.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Anti-HBs antibody concentration

Secondary Outcome Measures

Name	Time	Method
Sol & unsol symptoms after HBV vaccination, SAEs
Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.

Trial Locations

Locations (1)

GSK Investigational Site; 🇩🇪 Hamburg, Germany